Intracranial drug-delivery scaffolds: Biocompatibility evaluation of SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) gels
-
Add time:09/25/2019 Source:sciencedirect.com
Introduction: SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) (SAIB) is a water insoluble, biodegradable gel used for controlled-release oral and subcutaneous drug delivery. We investigated SAIB compatibility in the rat central nervous system (CNS) by implanting solutions of SAIB in adult and in neonatal brains. Methods: 10–15 μL solutions of SAIB gels in 0–30% ethanol were injected into the cerebral cortex of adult Fischer 344 rats. Control animals were implanted with a 10 mg biodegradable poly anhydride copolymer of poly [bis (p-carboxyphenoxy) propane] anhydride and sebacic acid (PCPP:SA). Adult rats were evaluated for signs of pain and distress, including changes in posture, facial signs, and grooming behavior. 1–2 μL solutions of SAIB gels in 15% ethanol were injected into brains of 12–24 h-old rats. Neonatal rats were evaluated for survival. Adult and neonatal brains were examined by histopathology 3–48 days after implant. Results: Gel implants produced elliptical compression of cortical tissue, cell loss, and inflammation. Cell loss appeared to be confined to the implantation wound and associated neuronal fields. In adult rats, neurophil compression, inflammation, and cell loss appeared similar with the 10-mg PCPP:SA implants and the 10-mg SAIB implants. There was no clinical evidence of pain or distress from SAIB implants. 1–2 μL implants of SAIB–15% ethanol had no effect on survival of neonatal animals. Conclusion: Brain implants of SAIB induce a mild to moderate inflammatory response and associated neuronal cell damage. The implants appeared to be biocompatible in adult and neonatal animals. These results suggest that further studies of SAIB as an injectable drug-delivery scaffold for CNS therapeutic agents are warranted.
We also recommend Trading Suppliers and Manufacturers of SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6). Pls Click Website Link as below: cas 126-13-6 suppliers
Prev:In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6)
Next:Research SectionLack of genotoxic effects of SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) (SAIB)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research SectionStudies on the metabolism of SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) in the rat and in man09/28/2019
- ReviewMetabolism and pharmacokinetics of SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) (SAIB) and sucrose octaisobutyrate (SOIB) in rats, dogs, monkeys or humans: a review10/01/2019
- Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) based delivery system09/27/2019
- Research SectionLack of genotoxic effects of SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) (SAIB)09/26/2019
- In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6)09/24/2019
- Research ArticlePharmaceutics, Drug Delivery and Pharmaceutical TechnologyImprovement of the Antitumor Efficacy of Intratumoral Administration of Cucurbitacin Poly(Lactic-co-Glycolic Acid) Microspheres Incorporated in In Situ-Forming SUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) Depots09/10/2019
- Research ArticlesSUCROSE ACETATE ISOBUTYRATE (cas 126-13-6) as an In Situ forming system for sustained risperidone release09/09/2019
-
Health and Chemical more >


